Sovargen
Industry · 2 registered clinical trials — 1 currently recruiting.
| Status | Trial | Phase | Started |
|---|---|---|---|
| Not Yet Recruiting | Safety, Tolerability, and Pharmacokinetics of SVG103 (Paxalisib) in Focal Cortical Dysplasia Type II (FCD-II), Focal Cortical Dysplasia, Tuberous Sclerosis Complex (TSC), Hemimegalencephaly | Phase 1 / Phase 2 | 2026-03-01 |
| Completed | Randomized Crossover of SVG101(Dispersible Tab. of Everolimus) and Afinitor 5mg in Healthy Adults Pharmacokinetics | Phase 1 | 2021-07-23 |